Sandy Adjemian

Sandy Adjemian

Auto-generated profile, based on publicly available information

Sandy Adjemian

Department of Biomedical Molecular Biology, Gent University, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JNJulie Le Naour
Julie Le Naour
PLPeng Liu
Peng Liu
LZLiwei Zhao
Liwei Zhao
SASandy Adjemian
Sandy Adjemian
ZSZsofia Sztupinszki
Zsofia Sztupinszki
Guido KroemerGuido Kroemer
Guido Kroemer
For anthracycline-based chemotherapy to be immunogenic, dying cancer cells must release annexin A1 (ANXA1) that subsequently interacts with the pattern recognition receptor, formyl peptide receptor 1 (FPR1), on the surface of dendritic cells (DC). Approximately 30% of individuals bear loss-of-function alleles of FPR1, calling for strategies to ameliorate their anticancer immune response. Here, we show that immunotherapy with a ligand of Toll-like receptor-3, polyinosinic:polycytidylic acid (pIC), restores the deficient response to chemotherapy of tumors lacking ANXA1 developing in immunocompetent mice or those of normal cancers growing in FPR1-deficient mice. This effect was accompanied by improved DC- and T-lymphocyte–mediated anticancer immunity. Of note, carcinogen-induced breast cancers precociously developed in FPR1-deficient mice as compared with wild-type controls. A similar tendency for earlier cancer development was found in patients carrying the loss-of-function allele of FPR1. These findings have potential implications for the clinical management of FPR1-deficient patients. Significance: The loss-of-function variant rs867228 in FPR1, harbored by approximately 30% of the world population, is associated with the precocious manifestation of breast, colorectal, esophageal, and head and neck carcinomas. pIC restores deficient chemotherapeutic responses in mice lacking Fpr1, suggesting a personalized strategy for compensating for the FPR1 defect. This article is highlighted in the In This Issue feature, p. 211

15 February 2020 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
TATania Løve Aaes
Tania Løve Aaes
HVHanne Verschuere
Hanne Verschuere
AKAgnieszka Kaczmarek
Agnieszka Kaczmarek
LHLiesbeth Heyndrickx
Liesbeth Heyndrickx
BWBartosz Wiernicki
Bartosz Wiernicki
PVPeter Vandenabeele
Peter Vandenabeele
Immunogenic cell death (ICD) occurs when a dying cell releases cytokines and damage-associated molecular patterns, acting as adjuvants, and expresses Ags that induce a specific antitumor immune response. ICD is studied mainly in the context of regulated cell death pathways, especially caspase-mediated apoptosis marked by endoplasmic reticulum stress and calreticulin exposure and, more recently, also in relation to receptor-interacting protein kinase–driven necroptosis, whereas unregulated cell death like accidental necrosis is nonimmunogenic. Importantly, the murine cancer cell lines used in ICD studies often express virally derived peptides that are recognized by the immune system as tumor-associated Ags. However, it is unknown how different cell death pathways may affect neoepitope cross-presentation and Ag recognition of cancer cells. We used a prophylactic tumor vaccination model and observed that both apoptotic and necroptotic colon carcinoma CT26 cells efficiently immunized mice against challenge with a breast cancer cell line that expresses the same immunodominant tumor Ag, AH1, but only necroptotic CT26 cells would mount an immune response against CT26-specific neoepitopes. By CRISPR/Cas9 genome editing, we knocked out AH1 and saw that only necroptotic CT26 cells were still able to protect mice against tumor challenge. Hence, in this study, we show that endogenous AH1 tumor Ag expression can mask the strength of immunogenicity induced by different cell death pathways and that upon knockout of AH1, necroptosis was more immunogenic than apoptosis in a prophylactic tumor vaccination model. This work highlights necroptosis as a possible preferred ICD form over apoptosis in the treatment of cancer.

3 April 2023
Verified
Other
Open access
JNJulie Le Naour
Julie Le Naour
PLPeng Liu
Peng Liu
LZLiwei Zhao
Liwei Zhao
SASandy Adjemian
Sandy Adjemian
ZSZsofia Sztupinszki
Zsofia Sztupinszki
GKGuido Kroemer
Guido Kroemer
Supplementary Figures and Tables

3 April 2023
Verified
Other
Open access
JNJulie Le Naour
Julie Le Naour
PLPeng Liu
Peng Liu
LZLiwei Zhao
Liwei Zhao
SASandy Adjemian
Sandy Adjemian
ZSZsofia Sztupinszki
Zsofia Sztupinszki
GKGuido Kroemer
Guido Kroemer
For anthracycline-based chemotherapy to be immunogenic, dying cancer cells must release annexin A1 (ANXA1) that subsequently interacts with the pattern recognition receptor, formyl peptide receptor 1 (FPR1), on the surface of dendritic cells (DC). Approximately 30% of individuals bear loss-of-function alleles of FPR1, calling for strategies to ameliorate their anticancer immune response. Here, we show that immunotherapy with a ligand of Toll-like receptor-3, polyinosinic:polycytidylic acid (pIC), restores the deficient response to chemotherapy of tumors lacking ANXA1 developing in immunocompetent mice or those of normal cancers growing in FPR1-deficient mice. This effect was accompanied by improved DC- and T-lymphocyte–mediated anticancer immunity. Of note, carcinogen-induced breast cancers precociously developed in FPR1-deficient mice as compared with wild-type controls. A similar tendency for earlier cancer development was found in patients carrying the loss-of-function allele of FPR1. These findings have potential implications for the clinical management of FPR1-deficient patients.Significance:The loss-of-function variant rs867228 in FPR1, harbored by approximately 30% of the world population, is associated with the precocious manifestation of breast, colorectal, esophageal, and head and neck carcinomas. pIC restores deficient chemotherapeutic responses in mice lacking Fpr1, suggesting a personalized strategy for compensating for the FPR1 defect.This article is highlighted in the In This Issue feature, p. 211

3 April 2023
Verified
Other
Open access
JNJulie Le Naour
Julie Le Naour
PLPeng Liu
Peng Liu
LZLiwei Zhao
Liwei Zhao
SASandy Adjemian
Sandy Adjemian
ZSZsofia Sztupinszki
Zsofia Sztupinszki
GKGuido Kroemer
Guido Kroemer

3 April 2023
Verified
Other
Open access
JNJulie Le Naour
Julie Le Naour
PLPeng Liu
Peng Liu
LZLiwei Zhao
Liwei Zhao
SASandy Adjemian
Sandy Adjemian
ZSZsofia Sztupinszki
Zsofia Sztupinszki
GKGuido Kroemer
Guido Kroemer
Supplementary Figures and Tables